المؤلفون: Shafaqat M Rahman, Anne E Luebke

مصطلحات موضوعية: Neuroscience, Endocrinology, Psychiatry (incl. Psychotherapy), Neurology and Neuromuscular Diseases, Pharmacology and Pharmaceutical Sciences not elsewhere classified, Psychology not elsewhere classified, CGRP, gastric distress, migraine, motion-sickness, mouse, nausea, olcegepant, rizatriptan, sumatriptan, vestibular

العلاقة: https://figshare.com/articles/journal_contribution/sj-pdf-1-cep-10_1177_03331024231223971_-_Supplemental_material_for_Calcitonin_gene-related_peptide_receptor_antagonism_reduces_motion_sickness_indicators_in_mouse_migraine_models/24994633Test

الإتاحة: https://doi.org/10.25384/sage.24994633.v1Test
https://figshare.com/articles/journal_contribution/sj-pdf-1-cep-10_1177_03331024231223971_-_Supplemental_material_for_Calcitonin_gene-related_peptide_receptor_antagonism_reduces_motion_sickness_indicators_in_mouse_migraine_models/24994633Test

المؤلفون: Shafaqat M Rahman, Anne E Luebke

مصطلحات موضوعية: Neuroscience, Endocrinology, Psychiatry (incl. Psychotherapy), Neurology and Neuromuscular Diseases, Pharmacology and Pharmaceutical Sciences not elsewhere classified, Psychology not elsewhere classified, CGRP, gastric distress, migraine, motion-sickness, mouse, nausea, olcegepant, rizatriptan, sumatriptan, vestibular

العلاقة: https://figshare.com/articles/journal_contribution/sj-pdf-2-cep-10_1177_03331024231223971_-_Supplemental_material_for_Calcitonin_gene-related_peptide_receptor_antagonism_reduces_motion_sickness_indicators_in_mouse_migraine_models/24994636Test

الإتاحة: https://doi.org/10.25384/sage.24994636.v1Test
https://figshare.com/articles/journal_contribution/sj-pdf-2-cep-10_1177_03331024231223971_-_Supplemental_material_for_Calcitonin_gene-related_peptide_receptor_antagonism_reduces_motion_sickness_indicators_in_mouse_migraine_models/24994636Test

المؤلفون: Zhong, Chao, Zhang, Xiufeng, Sun, Yanfang, Shen, Zhong, Mao, Yanan, Liu, Tianqi, Wang, Rui, Nie, Lei, Shavandi, Amin, Yunusov, Khaydar, Jiang, Guohua

المصدر: Journal of biomaterials applications

مصطلحات موضوعية: Sciences bio-médicales et agricoles, Sciences de l'ingénieur, Microneedles, migraine, rizatriptan benzoate, transdermal drug delivery

وصف الملف: 1 full-text file(s): application/pdf

العلاقة: uri/info:doi/10.1177/08853282241237323; uri/info:pmid/38427917; uri/info:scp/85186598621; https://dipot.ulb.ac.be/dspace/bitstream/2013/369607/3/Manuscript.pdfTest; http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/369607Test

الإتاحة: http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/369607Test
https://dipot.ulb.ac.be/dspace/bitstream/2013/369607/3/Manuscript.pdfTest

المؤلفون: Upadhyay, Jyotsna, Sonaji, Amle Vandana, Naaz, Farha

المصدر: Journal for Research in Applied Sciences and Biotechnology; Vol. 3 No. 2 (2024): April Issue; 233-241 ; 2583-4053

مصطلحات موضوعية: Rizatriptan, ODDS, Hardness test, LOD, LOQ, Tablet formulation

وصف الملف: application/pdf

العلاقة: https://jrasb.com/index.php/jrasb/article/view/524/466Test; https://jrasb.com/index.php/jrasb/article/view/524Test

الإتاحة: https://doi.org/10.55544/jrasb.3.2.40Test
https://jrasb.com/index.php/jrasb/article/view/524Test

المؤلفون: Kaushik Suhagiya, Chetan H. Borkhataria, Sumit Gohil, Ravi A. Manek, Kalpesh A. Patel, Nilesh K. Patel, Dhaval V. Patel

المصدر: Results in Chemistry, Vol 6, Iss , Pp 101010- (2023)

مصطلحات موضوعية: Rizatriptan, Mucoadhesive, In-situ nasal gel, Carbopol 934P, HPMC K4M, Chemistry, QD1-999

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S2211715623002497Test; https://doaj.org/toc/2211-7156Test

الوصول الحر: https://doaj.org/article/7a46d31108564f80bc3fba355a35880dTest

المؤلفون: Malini S., Raj Kalyan, Kumari Latha, Jayant Lakshmi, Shettihalli Ashok Kumar, Appaji Abhishek

المصدر: Open Chemistry, Vol 21, Iss 1, Pp 1-7 (2023)

مصطلحات موضوعية: rizatriptan benzoate, oxidation product, kinetics, chloramine t, spectrophotometric analysis, 1h and 13c nuclear magnetic resonance, indole, imide, Chemistry, QD1-999

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2391-5420Test

الوصول الحر: https://doaj.org/article/1ca1e03cc815477abe3184d0f75f1371Test

المؤلفون: Latha, Pushpa E.¹, Sailaja, B.

المصدر: Research Journal of Pharmacy and Technology 14(11):6003-6006. 2021

المؤلفون: G. R. Tabeeva, Г. Р. Табеева

المساهمون: This article has been supported by NovaMedica, Статья спонсируется компанией «НоваМедика»

المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 15, No 5 (2023); 109-116 ; Неврология, нейропсихиатрия, психосоматика; Vol 15, No 5 (2023); 109-116 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2023-5

مصطلحات موضوعية: ризатриптан, relief of migraine attacks, triptans, rizatriptan, купирование приступов мигрени, триптаны

وصف الملف: application/pdf

العلاقة: https://nnp.ima-press.net/nnp/article/view/2112/1592Test; Amiri P, Kazeminasab S, Nejadghaderi SA, et al. Migraine: A Review on Its History, Global Epidemiology, Risk Factors, and Comorbidities. Front Neurol. 2022 Feb 23;12:800605. doi:10.3389/fneur.2021.800605; Safiri S, Pourfathi H, Eagan A, et al. Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. Pain. 2022 Feb 1;163(2):e293e309. doi:10.1097/j.pain.0000000000002275; Burch RC, Buse DC, Lipton RB. Migraine: Epidemiology, Burden, and Comorbidity. Neurol Clin. 2019 Nov;37(4):631-49. doi:10.1016/j.ncl.2019.06.001; Ayzenberg I, Katsarava Z, Sborowski A, et al; Lifting the Burden. The prevalence of primary headache disorders in Russia: a countrywide survey. Cephalalgia. 2012 Apr;32(5):37381. doi:10.1177/0333102412438977; Steiner TJ, Stovner LJ, Jensen R, et al. Lifting The Burden: the Global Campaign against Headache. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020 Dec 2;21(1):137. doi:10.1186/s10194-020-01208-0; Steiner TJ, Stovner LJ, Vos T, et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018 Feb 21;19(1):17. doi:10.1186/s10194-018-0846-2; Кирьянова ЕА, Табеева ГР. Гормональная терапия менструально-ассоциированной мигрени: за и против. Неврология, нейропсихиатрия, психосоматика. 2022;14(1):6975. doi:10.14412/2074-2711-2022-1-69-75; Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211. doi:10.1177/0333102417738202; Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-14. doi:10.1038/s41582-02100509-5; Lucas C, Geraud G, Valade D, et al. Recognition and therapeutic management of migraine in 2004, in France: results of FRAMIG 3, a French nationwide population-based survey. Headache. 2006 May;46(5):715-25. doi:10.1111/j.15264610.2006.00430.x; Lipton RB, Stewart WF, Celentano DD, Reed ML. Undiagnosed migraine headaches. A comparison of symptom-based and reported physician diagnosis. Arch Intern Med. 1992 Jun;152(6):1273-8. doi:10.1001/archinte.152.6.1273; Lipton RB, Bigal ME, Diamond M, et al, AMPP Advisory Group: Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343-9. doi:10.1212/01.wnl.0000252808.97649.21; Lipton RB, Manack AN, Serrano D, Buse DC. Acute treatment optimization for migraine: results of the American migraine prevalence and prevention (AMPP) study. J Headache Pain. 2013;14(Suppl 1):P201. doi:10.1186/1129-2377-1-S14-P201; Ковальчук НА, Кирьянова ЕА, Табеева ГР. Приверженность терапии пациентов с мигренью (по данным интернетопроса). Неврология, нейропсихиатрия, психосоматика. 2021;13(4):81-7. doi:10.14412/2074-2711-2021-4-81-87; Мигрень. Клинические рекомендации МЗ РФ. 2021. [Migren'. Klinicheskie rekomendatsii MZ RF; VanderPluym JH, Halker Singh RB, Urtecho M, et al. Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis. JAMA. 2021 Jun 15;325(23):2357-69. doi:10.1001/jama.2021.7939; Silberstein SD, Holland S, Freitag F, et al; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidencebased guideline update: pharmacologic treat ment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012 Apr 24;78(17):1337-45. doi:10.1212/WNL.0b013e3182535d20; Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3-20. doi:10.1111/head.12499; Nicolas S, Nicolas D. Triptans. Treasure Island (FL): StatPearls Publishing; 2022.; Szkutnik-Fiedler D. Pharmacokinetics, pharmacodynamics and drug-drug interactions of new anti-migraine drugs: lasmiditan, gepants, and calcitonin-gene-related peptide (CGRP) receptor monoclonal antibodies. Pharmaceutics. 2020;12 (12):E1180. doi:10.3390/pharmaceutics12121180; Табеева ГР, Амелин АВ, Ахмадеева ЛР и др. Оптимизация купирования приступов мигрени. Неврология, нейропсихиатрия, психосоматика. 2023;15(2):126-33. doi:10.14412/2074-2711-2023-2-126-133; Johnson B, Freitag FG. New Approaches to Shifting the Migraine Treatment Paradigm. Front Pain Res (Lausanne). 2022 Sep 6;3:873179. doi:10.3389/fpain.2022.873179; Maassen Van Den Brink A, Saxena PR. Coronary vasoconstrictor potential of triptans: a review of in vitro pharmacologic data. Headache. 2004;44(Suppl 1):S13-S19. doi:10.1111/j.15264610.2004.04104.x; Ahn AH, Basbaum AI. Where do triptans act in the treatment of migraine? Pain. 2005;115(1-2):1-4. doi:10.1016/j.pain.2005.03.008; Sacco S, Lampl C, Amin FM, et al. European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain. 2022 Oct 12;23(1):133. doi:10.1186/s10194-022-01502-z; Charleston Iv L, Burke JF. Do racial/ethnic disparities exist in recommended migraine treatments in US ambulatory care? Cephalalgia. 2018 Apr;38(5):876-82. doi:10.1177/0333102417716933. Epub 2017 Jun 26.; Diamond S, Bigal ME, Silberstein S, et al. Patterns of Diagnosis and Acute and Preventive Treatment for Migraine in the United States: Results from the American Migraine Prevalence and Prevention Study. Headache. 2007 Mar;47(3):355-63. doi:10.1111/j.15264610.2006.00631.x. Erratum in: Headache. 2007 Oct;47(9):1365.; Ковальчук НА, Гузий ЕА, Табеева ГР. Особенности пациентов с частой эпизодической и хронической мигренью. Доктор.Ру. 2022;21(4):13-8. doi:10.31550/1727-2378-2022-21-4-13-18; Lipton RB, Munjal S, Buse DC, et al. Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study. Headache. 2019 Sep;59(8):1310-23. doi:10.1111/head.13588; Lipton RB, Buse DC, Serrano D, et al. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2013 Sep;53(8):1300-11. doi:10.1111/head.12154. Epub 2013 Jul 23.; Табеева ГР, Осипова ВВ, Филатова ЕГ и др. Диагностика и лечение лекарственноиндуцированной головной боли: рекомендации российских экспертов. Неврология, нейропсихиатрия, психосоматика. 2022;14(1):4-13. doi:10.14412/2074-27112022-1-4-13; Viana M, Genazzani AA, Terrazzino S, et al. Triptan nonresponders: do they exist and who are they? Cephalalgia. 2013;33(11):891-6. doi:10.1177/0333102413480756; Ferrari A, Pinetti D, Bertolini A, et al. Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients. Eur J Clin Pharmacol. 2008;64(5):489-95. doi:10.1007/s00228-0070443-9; Cady RK, Vause CV, Ho TW, et al. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache. 2009;49(9):1258-66. doi:10.1111/j.1526-4610.2009.01523.x; Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001 Nov 17;358(9294):1668-75. doi:10.1016/S0140-6736(01)06711-3; Cameron C, Kelly S, Hsieh SC. Triptans in the acute treatment of migraine: A systematic review and network meta-analysis. Headache. 2015;55(Suppl 4):221-35. doi:10.1111/head.12601; Block GA, Goldstein J, Polis A. On behalf of the Rizatriptan Multicenter Study Groups. Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Headache. 1998 Nov-Dec;38(10):764-71.; Jhee SS, Shiovitz T, Crawford AW, Cutler NR. Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin Pharmacokinet. 2001;40(3):189-205. doi:10.2165/00003088200140030-00004; Goadsby PJ, Hargreaves RJ. Mechanisms of action of serotonin 5-HT1B/1D agonists: insights into migraine pathophysiology using rizatriptan. Neurology. 2000;55(9 Suppl 2):S8-14.; Dooley M, Faulds D. Rizatriptan: a review of its efficacy in the management of migraine. Drugs. 1999 Oct;58(4):699-723. doi:10.2165/00003495-199958040-00013; Williamson DJ, Hill RG, Shepheard SL, Hargreaves RJ. The anti-migraine 5HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guineapigs. Br J Pharmacol. 2001 Aug;133(7):1029-34. doi:10.1038/sj.bjp.0704162; Cumberbatch MJ, Hill RG, Hargreaves RJ. Rizatriptan has central antinociceptive effects against durally evoked responses. Eur J Pharmacol. 1997;328:37-40. doi:10.1016/s0014-2999(97)83024-5; Hargreaves RJ, Lines CR, Rapoport AM, et al. Ten years of rizatriptan: from development to clinical science and future directions. Headache. 2009 Feb;49 Suppl 1:S3-20. doi:10.1111/j.1526-4610.2008.01335.x; Ferrari MD, Loder E, McCarroll KA, Lines CR. Meta-analysis of rizatriptan efficacy in randomized controlled clinical trials. Cephalalgia. 2001;21:129-36. doi:10.1046/j.1468-2982.2001.00169.x; Belsey J. Reconciling effectiveness and tolerability in oral triptan therapy: a quantitative approach to decision making in migraine management. J Clin Res. 2001;4:105-25.; Kramer MS, Matzura-Wolfe D, Polis A, et al. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group. Neurology. 1998 Sep;51(3):77381. doi:10.1212/wnl.51.3.773; Сергеев АВ, Табеева ГР, Филатова ЕГ и др. Применение новой биологической патогенетической терапии мигрени в клинической практике: консенсус экспертов Российского общества по изучению головной боли. Неврология, нейропсихиатрия, психосоматика. 2022;14(5):109-16. doi:10.14412/2074-2711-2022-5-109-116; Rapoport AM, Tepper SJ, Sheftell FD, et al. Which triptan for which patient? Neurol Sci. 2006 May;27 Suppl 2:S123-9. doi:10.1007/s10072-006-0586-y; De Boer I, Verhagen IE, Souza MNP, Ashina M. Place of next generation acute migraine specific treatments among triptans, non-responders and contraindications to triptans and possible combination therapies. Cephalalgia. 2023 Feb;43(2):3331024221143773. doi:10.1177/03331024221143773; Cortelli P, Allais G, Benedetto C. Overview of Triptans in the Treatment of Acute Migraine. Eur Neurol Rev. 2017;12(2):71-7. doi:10.17925/ENR.2017.12.02.71; Ceballos Hernansanz MA, Sanchez Roy R, Cano Orgaz A, Lopez-Gil A; START 10 Study Group. Migraine treatment patterns and patient satisfaction with prior therapy: a substudy of a multicenter trial of rizatriptan effectiveness. Clin Ther. 2003 Jul;25(7):2053-69. doi:10.1016/s0149-2918(03)80204-7; McMahon G. Triptans for migraine: how should triptans be used? 2010. Available from: http://blogs.nejm.org/now/index.phpTest/ triptans-for-migraine-how-shouldtriptans-be-used/2010/07/02/ (accessed 23.02.2017).; Bigal M, Rapoport A, Aurora S, et al. Satisfaction with current migraine therapy: experience from 3 centers in US and Sweden. Headache. 2007 Apr;47(4):475-9. doi:10.1111/j.1526-4610.2007.00752.x; Leroux E, Buchanan A, Lombard L, et al. Evaluation of Patients with Insufficient Efficacy and/or Tolerability to Triptans for the Acute Treatment of Migraine: A Systematic Literature Review. Adv Ther. 2020 Dec;37(12):4765-96. doi:10.1007/s12325-020-01494-9; Olesen A, Schytz HW, Ostrowski SR, et al. Low adherence to the guideline for the acute treatment of migraine. Sci Rep. 2022 May 19;12(1):8487. doi:10.1038/s41598-022-12545-2; Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache. 2002 Jan;42 Suppl 1:3-9. doi:10.1046/j.15264610.2002.0420s1003.x; Cutrer FM, Goadsby PJ, Ferrari MD, et al. Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR Project). Clin Ther. 2004 Sep;26(9):1533-45. doi:10.1016/j.clinthera.2004.09.011; Gerth WC, McCarroll KA, Santanello NC, et al. Patient satisfaction with rizatriptan vs other triptans: Direct head-to head comparisons. Int J Clin Pract. 2001 Oct;55(8):552-6.; Pascual J, Fite B, Lopez-Gil A. Comparison of triptan tablet consumption per attack: a prospective study of migraineurs in Spain. Headache. 2002 Feb;42(2):93-8. doi:10.1046/j.1526-4610.2002.02024.x; Хохлов АЛ, Лейкин ЗН. Сравнительное клиническое исследование фармакокинетики и биоэквивалентности препаратов ризатриптана Релонова и Максалт. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023;123(8):1-7. doi:10.17116/jnevro20231230811; https://nnp.ima-press.net/nnp/article/view/2112Test

الإتاحة: https://doi.org/10.14412/2074-2711-2023-5-109-116Test
https://doi.org/10.14412/2074-2711-2023-5Test
https://doi.org/10.3389/fneur.2021.800605Test
https://doi.org/10.1097/j.pain.0000000000002275Test
https://doi.org/10.1016/j.ncl.2019.06.001Test
https://doi.org/10.1177/0333102412438977Test
https://doi.org/10.1186/s10194-020-01208-0Test
https://doi.org/10.14412/2074-2711-2022-1-69-75Test
https://doi.org/10.1177/0333102417738202Test
https://doi.org/10.1038/s41582-02100509-5Test

المؤلفون: G. R. Tabeeva, A. V. Amelin, L. R. Akhmadeeva, A. B. Danilov, O. B. Doronina, M. I. Koreshkina, N. V. Latysheva, E. G. Mendelevich, I. V. Sarvilina, A. V. Sergeev, K. V. Skorobogatykh, E. G. Filatova, Г. Р. Табеева, А. В. Амелин, Л. Р. Ахмадеева, А. Б. Данилов, О. Б. Доронина, М. И. Корешкина, Н. В. Латышева, Е. Г. Менделевич, И. В. Сарвилина, А. В. Сергеев, К. В. Скоробогатых, Е. Г. Филатова

المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 15, No 2 (2023); 126-133 ; Неврология, нейропсихиатрия, психосоматика; Vol 15, No 2 (2023); 126-133 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2023-2

مصطلحات موضوعية: орально диспергируемая таблетка, clinical guidelines, migraine, therapy, rizatriptan, Kaporiza®, orally dispersible tablet, клинические рекомендации, мигрень, терапия, ризатриптан, Капориза®

وصف الملف: application/pdf

العلاقة: https://nnp.ima-press.net/nnp/article/view/2005/1523Test; World Health Organization. Atlas of headache disorders and resources in the world 2011. A collaborative project of World Health Organization and Lifting The Burden. 2011. ISBN: 9789241564212; GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1204-22. doi:10.1016/S0140-6736(20)30925-9; Steiner TJ, Stovner LJ, Jensen R, et al; Lifting The Burden: the Global Campaign against Headache. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020 Dec 2;21(1):137. doi:10.1186/s10194-020-01208-0; Табеева ГР. Головные боли в общеврачебной практике. Терапевтический архив. 2022;94(1):114-21. doi:10.26442/00403660.2022.01.201325; Diener HC, Tassorelli C, Dodick DW, et al. Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. Cephalalgia. 2019;39(6):687-710. doi:10.1177/0333102419828967; Silberstein SD, Newman LC, Marmura MJ, et al. Efficacy endpoints in migraine clinical trials: the importance of assessing freedom from pain. Curr Med Res Opin. 2013 Jul;29(7):861-7. doi:10.1185/03007995.2013.787980. Epub 2013 May 22.; Food and Drug Administration. Migraine: developing drugs for acute treatment. Guidance for industry. 2018. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm419465.pdfTest (accessed 18.07.2018).; Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015 Jan;55(1):3-20. doi:10.1111/head.12499; Lipton RB, Buse DC, Adams AM, et al. Treatment Patterns and Unmet Needs in the Acute Treatment of Migraine. J Fam Pract. 2020 Jan/Feb;69(1 Suppl):S1-S7.; Mayans L, Walling A. Acute migraine headache: treatment strategies. Am Fam Physician. 2018 Feb 15;97(4):243-51.; Hutchinson S, Lipton RB, Ailani J, et al. Characterization of Acute Prescription Migraine Medication Use: Results From the CaMEO Study. Mayo Clin Proc. 2020 Apr;95(4):709-18. doi:10.1016/j.mayocp.2019.11.025; Lipton RB, Munjal S, Alam A, et al. Migraine in America Symptoms and Treatment (MAST) Study: Baseline study methods, treatment patterns, and gender differences. Headache. 2018;58(9):1408-26. doi:10.1111/head.13407; Katic BJ, Rajagopalan S, Ho TW, et al. Triptan persistency among newly initiated users in a pharmacy claims database. Cephalalgia. 2011;31(4):488-500. doi:10.1177/0333102410383058; Serrano D, Buse DC, Kori SH, et al. Effects of switching acute treatment on disability in migraine patients using triptans. Headache. 2013;53(9):1415-29. doi:10.1111/head.12164; Lanteri-Minet M, Massiou H, Romatet S, et al. An instrument to assess patient perception of satisfaction with acute migraine treatment (EXPERT Study). Headache. 2011;51:590-601. doi:10.1111/j.1526-4610.2011.01867.x; Bigal ME, Borucho S, Serrano D, et al. The acute treatment of episodic and chronic migraine in the US. Cephalalgia. 2009;29:891-7. doi:10.1111/j.1468-2982.2008.01819.x; Табеева ГР, Кацарава З, Амелин АВ и др. Новое в осознании бремени мигрени: семантический анализ голоса российских пациентов – пользователей Web 2.0. Неврология, нейропсихиатрия, психосоматика. 2021;13(6):73-84. doi:10.14412/2074-2711-2021-6-73-84; Bigal ME, Serrano D, Buse D, et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal populationbased study. Headache. 2008;48(8):1157-68. doi:10.1111/j.1526-4610.2008.01217.x; Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. doi:10.1177/0333102417738202; Ailani J, Burch RC, Robbins MS on behalf of the Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39. doi:10.1111/head.14153. Epub 2021 Jun 23.; Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the quality standards subcommittee of the American academy of neurology. Neurology. 2000;55(6):754-62. doi:10.1212/wnl.55.6.754; Табеева ГР. Специфическое лечение мигрени: история одного триптана. Журнал неврологии и психиатрии им. С.С. Корсакова. 2007;(5):75-8.; Migraine: developing drugs for acute treatment [Internet]. Food and Drug Administration; 2018. Available from: https://www.fda.gov/regulatoryinformation/search-fdaguidancedocuments/migraine-developingdrugs-acute-treatmentTest (accessed 16.01.2020).; Cameron C, Kelly S, Hsieh SC, et al. Triptans in the acute treatment of migraine: A systematic review and network meta-analysis. Headache. 2015;55(Suppl 4):221-35. doi:10.1111/head.12601; Cutrer FM, Goadsby PJ, Ferrari MD, et al. Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR Project). Clin Ther. 2004 Sep;26(9):1533-45. doi:10.1016/j.clinthera.2004.09.011; Sacco S, Lampl C, Amin FM, et al. European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain. 2022 Oct 12;23(1):133. doi:10.1186/s10194-022-01502-z; Oswald JC, Schuster NM. Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice. J Pain Res. 2018;11:2221-7. doi:10.2147/JPR.S152216; Hepp Z, Dodick DW, Varon SF, et al. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):478-88. doi:10.1177/0333102414547138; Silberstein SD. Migraine symptoms: results of a survey of self reported migraineurs. Headache. 1995;35:38. doi:10.1111/j.1526-4610.1995.hed3507387.x; Dahlof CGH, Hargreaves RJ. Pathophysiology and pharmacology of migraine: is there a place for antiemetics in future treatment strategies. Cephalalgia. 1998;18:593-604. doi:10.1046/j.1468-2982.1998.1809593.x; Schurks M, Buring JE, Kurth T. Migraine, migraine features, and cardiovascular disease. Headache. 2010;50:1031-40. doi:10.1111/j.1526-4610.2009.01609.x; May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol. 2016 Aug;12(8):455-64. doi:10.1038/nrneurol.2016.93; Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache. 1999;39 Suppl.2:20-6. doi:10.1046/j.1526-4610.2002.0420s1003.x; Aurora SK, Papapetropoulos S, Kori SH, et al. Gastric stasis in migraineurs: etiology, characteristics, and clinical and therapeutic implications. Cephalalgia. 2013 Apr;33(6):408-15. doi:10.1177/0333102412473371; Masaoka T, Tack J. Gastroparesis: Current concepts and management. Gut Liver. 2009;3:166-73. doi:10.5009/gnl.2009.3.3.166; Waseem S, Moshiree B, Draganov PV. Gastroparesis: Current diagnostic challenges and management considerations. World J Gastroenterol. 2009;15:25-37. doi:10.5009/gnl.2009.3.3.166; Peroutka SJ. Re: A sympathetic view of “2003 Wolff Award: Possible parasympathetic contributions to peripheral and central sensitization during migraine”. Headache. 2004;44:731-32. doi:10.1111/j.1526-4610.2004.04134_5.x; Rapoport AM, Freitag F, Pearlman SH. Innovative delivery systems for migraine: The clinical utility of a transdermal patch for the acute treatment of migraine. CNS Drugs. 2010;24:929-40. doi:10.2165/11317540-000000000-00000; Volans GN. Absorption of effervescent aspirin during migraine. Br Med J. 1974;4:265-8. doi:10.1136/bmj.4.5939.265; Tokola RA, Neuvonen PJ. Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. Br J Clin Pharmacol. 1984;17:67-75. doi:10.1111/j.1365-2125.1984.tb05001.x; Aurora S, Kori S, Barrodale P, et al. Gastric stasis occurs in spontaneous, visually induced, and interictal migraine. Headache. 2007;47:1443-6. doi:10.1111/j.1526-4610.2007.00922.x; Thomsen LL, Dixon R, Lassen LH, et al. 311C90 (zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: A comparison of its absorption during a migraine attack and in a migraine-free period. Cephalalgia. 1996;16:270-5. doi:10.1046/j.1468-2982.1996.1604270.x; Krymchantowski AV, Filho PF, Bigal ME. Rizatriptan vs. rizatriptan plus trimebutine for the acute treatment of migraine: A doubleblind, randomized, crossover, placebo-controlled study. Cephalalgia. 2006;26:871-4. doi:10.1111/j.1468-2982.2006.01136.x; Marmura MJ. Use of dopamine antagonists in treatment of migraine. Curr Treat Options Neurol. 2012;14:27-35. doi:10.1007/s11940-011-0150-9; Habib W, Khankari R, Hontz J. Fast-dissolve drug delivery systems. Crit Rev Ther Drug Carrier Syst. 2000;17(1):61-72.; https://nnp.ima-press.net/nnp/article/view/2005Test

الإتاحة: https://doi.org/10.14412/2074-2711-2023-2-126-133Test
https://doi.org/10.14412/2074-2711-2023-2Test
https://doi.org/10.1016/S0140-6736Test(20)30925-9
https://doi.org/10.1186/s10194-020-01208-0Test
https://doi.org/10.26442/00403660.2022.01.201325Test
https://doi.org/10.1177/0333102419828967Test
https://doi.org/10.1185/03007995.2013.787980Test
https://doi.org/10.1111/head.12499Test
https://doi.org/10.1016/j.mayocp.2019.11.025Test
https://doi.org/10.1111/head.13407Test

المؤلفون: G. R. Tabeeva, O. V. Kosivtsova, Г. Р. Табеева, О. В. Косивцова

المصدر: Meditsinskiy sovet = Medical Council; № 21 (2023); 54-62 ; Медицинский Совет; № 21 (2023); 54-62 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: ризатриптан, relief of migraine attacks, stratification of migraine attacks, differentiated approach, specific anti-migraine drugs, triptans, rizatriptan, купирование приступов мигрени, стратификация приступов мигрени, дифференцированный подход, специфические антимигренозные средства, триптаны

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/7928/7041Test; GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11): 954–976. https://doi.org/10.1016/s1474-4422Test(18)30322-3.; Ashina M. Migraine. N Engl J Med. 2020;383(19):1866–1876. https://doi.org/10.1056/NEJMra1915327Test.; GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100): 1211–1259. https://doi.org/10.1016/S0140-6736Test(17)32154-2.; Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41(7):646–657. https://doi.org/10.1046/j.1526-4610.2001.041007646.xTest.; Азимова ЮЭ, Амелин АВ, Алферова ВВ, Артеменко АР, Ахмадеева ЛР, Головачева ВА и др. Мигрень: клинические рекомендации. М.; 2021. 87 с. Режим доступа: https://cr.minzdrav.gov.ru/schema/295_2Test.; VanderPluym JH, Halker Singh RB, Urtecho M, Morrow AS, Nayfeh T, Torres Roldan VD et al. Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis. JAMA. 2021;325(23):2357–2369. https://doi.org/10.1001/jama.2021.7939Test.; Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55(6):754–762. https://doi.org/10.1212/wnl.55.6.754Test.; Tfelt-Hansen P, Pascual J, Ramadan N, Dahlöf C, D’Amico D, Diener HC et al. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia. 2012;32(1):6–38. https://doi.org/10.1177/0333102411417901Test.; Ashina M, Buse DC, Ashina H, Pozo-Rosich P, Peres MFP, Lee MJ et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet. 2021;397(10283):1505–1518. https://doi.org/10.1016/S0140-6736Test(20)32342-4.; Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021;17(8):501–514. https://doi.org/10.1038/s41582-021-00509-5Test.; Guo S, Ernstsen C, Hay-Schmidt A, Kristensen DM, Ashina M, Olesen J, Christensen SL. PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine. J Headache Pain. 2022;23(1):155. https://doi.org/10.1186/s10194-022-01523-8Test.; Lipton RB, Buse DC, Serrano D, Holland S, Reed ML. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2013;53(8):1300–1311. https://doi.org/10.1111/head.12154Test.; Lipton RB, Stewart WF, Stone AM, Láinez MJ, Sawyer JP. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial. JAMA. 2000;284(20):2599–2605. https://doi.org/10.1001/jama.284.20.2599Test.; Sculpher M, Millson D, Meddis D, Poole L. Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: The Disability in Strategies for Care (DISC) Study. Pharmacoeconomics. 2002;20(2):91–100. https://doi.org/10.2165/00019053-200220020-00002Test.; Worthington I, Pringsheim T, Gawel MJ, Gladstone J, Cooper P, Dilli E et al. Canadian Headache Society Guideline: acute drug therapy for migraine headache. Can J Neurol Sci. 2013;40(Suppl. 3):S1–S80. https://doi.org/10.1017/S0317167100017819Test.; Steiner TJ, Jensen R, Katsarava Z, Linde M, MacGregor EA, Osipova V et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache. J Headache Pain. 2019;20(1):57. https://doi.org/10.1186/s10194-018-0899-2Test.; Katsarava Z, Mania M, Lampl C, Herberhold J, Steiner TJ. Poor medical care for people with migraine in Europe – evidence from the Eurolight study. J Headache Pain. 2018;19(1):10. https://doi.org/10.1186/s10194-018-0839-1Test.; Lipton RB, Fanning KM, Serrano D, Reed ML, Cady R, Buse DC. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology. 2015;84(7):688–695. https://doi.org/10.1212/WNL.0000000000001256Test.; Lipton RB, Nicholson RA, Reed ML, Araujo AB, Jaffe DH, Faries DE et al. Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study. Headache. 2022;62(2):122–140. https://doi.org/10.1111/head.14259Test.; Buse DC, Greisman JD, Baigi K, Lipton RB. Migraine Progression: A Systematic Review. Headache. 2019;59(3):306–338. https://doi.org/10.1111/head.13459Test.; Juhasz G, Gecse K, Baksa D. Towards precision medicine in migraine: Recent therapeutic advances and potential biomarkers to understand heterogeneity and treatment response. Pharmacol Ther. 2023;250:108523. https://doi.org/10.1016/j.pharmthera.2023.108523Test.; Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. https://doi.org/10.1177/0333102417738202Test.; Rasmussen BK, Jensen R, Olesen J. A population-based analysis of the diagnostic criteria of the International Headache Society. Cephalalgia. 1991;11(3):129–134. https://doi.org/10.1046/j.1468-2982.1991.1103129.xTest.; Lipton RB, Silberstein SD, Dodick DW. 3. Overview of Diagnosis and Classification. In: Silberstein SD, Lipton RB, Dodick DW (eds.). Wolff’s Headache and Other Head Pain. 8th ed. New York: Oxford University Press; 2007. Available at: https://global.oup.com/academic/product/wolffs-headache-and-other-head-pain-9780195326567Test.; Giffin NJ, Ruggiero L, Lipton RB, Silberstein SD, Tvedskov JF, Olesen J et al. Premonitory symptoms in migraine: an electronic diary study. Neurology. 2003;60(6):935–940. https://doi.org/10.1212/01.wnl.0000052998.58526.a9Test.; Hansen JM, Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK et al. Migraine headache is present in the aura phase: a prospective study. Neurology. 2012;79(20):2044–2049. https://doi.org/10.1212/WNL.0b013e3182749eedTest.; Villar-Martinez MD, Goadsby PJ. Pathophysiology and Therapy of Associated Features of Migraine. Cells. 2022;11(17):2767. https://doi.org/10.3390/cells11172767Test.; Silberstein SD. Migraine. Lancet. 2004;363(9406):381–391. https://doi.org/10.1016/S0140-6736Test(04)15440-8.; Munjal S, Singh P, Reed ML, Fanning K, Schwedt TJ, Dodick DW et al. Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study. Headache. 2020;60(2):416–429. https://doi.org/10.1111/head.13708Test.; Reed ML, Fanning KM, Serrano D, Buse DC, Lipton RB. Persistent frequent nausea is associated with progression to chronic migraine: AMPP study results. Headache. 2015;55(1):76–87. https://doi.org/10.1111/head.12450Test.; Kovacic K, Li BUK. Cyclic vomiting syndrome: A narrative review and guide to management. Headache. 2021;61(2):231–243. https://doi.org/10.1111/head.14073Test.; Ellingsen DM, Garcia RG, Lee J, Lin RL, Kim J, Thurler AH et al. Cyclic Vomiting Syndrome is characterized by altered functional brain connectivity of the insular cortex: A cross-comparison with migraine and healthy adults. Neurogastroenterol Motil. 2017;29(6):e13004. https://doi.org/10.1111/nmo.13004Test.; Venkatesan T, Levinthal DJ, Tarbell SE, Jaradeh SS, Hasler WL, Issenman RM et al. Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association. Neurogastroenterol Motil. 2019;31(Suppl. 2):e13604. https://doi.org/10.1111/nmo.13604Test.; Abouzari M, Cheung D, Pham T, Goshtasbi K, Sarna B, Tajran S et al. The Relationship Between Vestibular Migraine and Motion Sickness Susceptibility. Otol Neurotol. 2020;41(8):1116–1121. https://doi.org/10.1097/MAO.0000000000002705Test.; Marcus DA, Furman JM. Prevention of motion sickness with rizatriptan: a double-blind, placebo-controlled pilot study. Med Sci Monit. 2006;12(1): PI1–7. Available at: https://medscimonit.com/abstract/index/idArt/443201Test.; Silva-Néto RP, Peres MF, Valença MM. Odorant substances that trigger headaches in migraine patients. Cephalalgia. 2014;34(1):14–21. https://doi.org/10.1177/0333102413495969Test.; Schulte LH, Jürgens TP, May A. Photo-, osmo- and phonophobia in the premonitory phase of migraine: mistaking symptoms for triggers? J Headache Pain. 2015;16:14. https://doi.org/10.1186/s10194-015-0495-7Test.; Baldacci F, Lucchesi C, Ulivi M, Cafalli M, Vedovello M, Vergallo A et al. Clinical features associated with ictal osmophobia in migraine. Neurol Sci. 2015;36(1):43–46. https://doi.org/10.1007/s10072-014-1903-5Test.; Delussi M, Laporta A, Fraccalvieri I, de Tommaso M. Osmophobia in primary headache patients: associated symptoms and response to preventive treatments. J Headache Pain. 2021;22(1):109. https://doi.org/10.1186/s10194-021-01327-2Test.; Selby G, Lance JW. Observations on 500 cases of migraine and allied vascular headache. J Neurol Neurosurg Psychiatry. 1960;23(1):23–32. https://doi.org/10.1136/jnnp.23.1.23Test.; Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American headache society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3–20. https://doi.org/10.1111/head.12499Test.; Cooper W, Doty EG, Hochstetler H, Hake A, Martin V. The current state of acute treatment for migraine in adults in the United States. Postgrad Med. 2020;132(7):581–589. https://doi.org/10.1080/00325481.2020.1767402Test.; Cameron C, Kelly S, Hsieh SC, Murphy M, Chen L, Kotb A et al. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis. Headache. 2015;55(Suppl. 4):221–235. https://doi.org/10.1111/head.12601Test.; Hargreaves RJ. Pharmacology and potential mechanisms of action of rizatriptan. Cephalalgia. 2000;20(Suppl. 1):2–9. https://doi.org/10.1046/j.1468-2982.2000.020s1002.xTest.; Allen C. Rizatriptan: clinical update. In: Humphrey P, Ferrari M, Olesen J (eds.). The Triptans: Novel Drugs for Migraine. New York: Oxford University Press; 2001, pp. 199–205. Available at: https://global.oup.com/academic/product/the-triptans-novel-drugs-for-migraine-9780192632142Test.; Habib W, Khankari R, Hontz J. Fast-dissolve drug delivery systems. Crit Rev Ther Drug Carrier Syst. 2000;17(1):61–72. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.v17.i1.20Test.; Cady R, Crawford G, Ahrens S, Hairwassers D, Getson A, Visser WH, Lines C. Long-term efficacy and tolerability of rizatriptan wafers in migraine. MedGenMed. 2001;3(3):1. Available at: https://www.medscape.com/viewarticle/408137_0?form=fpfTest.; Sharma D, Singh G, Kumar D, Singh M. Formulation development and evaluation of fast disintegrating tablets of salbutamol sulphate, cetirizine hydrochloride in combined pharmaceutical dosage form: a new era in novel drug delivery for pediatrics and geriatrics. J Drug Deliv. 2015:640529. https://doi.org/10.1155/2015/640529Test.; Fu Y, Yang S, Jeong SH, Kimura S, Park K. Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies. Crit Rev Ther Drug Carrier Syst. 2004;21(6):433–476. https://doi.org/10.1615/critrevtherdrugcarriersyst.v21.i6.10Test.; Silberstein SD. Migraine symptoms: results of a survey of self-reported migraineurs. Headache. 1995;35(7):387–396. https://doi.org/10.1111/j.1526-4610.1995.hed3507387.xTest.; Adelman JU, Lipton RB, Ferrari MD, Diener HC, McCarroll KA, Vandormael K, Lines CR. Comparison of rizatriptan and other triptans on stringent measures of efficacy. Neurology. 2001;57(8):1377–1383. https://doi.org/10.1212/wnl.57.8.1377Test.; Tfelt-Hansen P, Ryan RE Jr. Oral therapy for migraine: comparisons between rizatriptan and sumatriptan. A review of four randomized, double-blind clinical trials. Neurology. 2000;55(Suppl. 2):S19–24. https://doi.org/10.1212/WNL.55.2.19ATest.; Ahrens SP, Farmer MV, Williams DL, Willoughby E, Jiang K, Block GA, Visser WH. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Cephalalgia. 1999;19(5):525–530. https://doi.org/10.1046/j.1468-2982.1999.019005525.xTest.; Lipton RB, Pascual J, Goadsby PJ, Massiou H, McCarroll KA, Vandormael K et al. Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis. Headache. 2001;41(8):754–763. https://doi.org/10.1046/j.1526-4610.2001.01139.xTest.; Табеева ГР, Амелин АВ, Ахмадеева ЛР, Данилов АБ, Доронина ОБ, Корешкина МИ и др. Оптимизация купирования приступов мигрени. Неврология, нейропсихиатрия, психосоматика. 2023;15(2):126–133. https://doi.org/10.14412/2074-2711-2023-2-126-133Test.; Табеева ГР, Кацарава З, Амелин АВ, Сергеев АВ, Скоробогатых КВ, Ефименко ИВ, Хорошевский ВФ. Новое в осознании бремени мигрени: семантический анализ голоса российских пациентов – пользователей Web 2.0. Неврология, нейропсихиатрия, психосоматика. 2021;13(6):73–84. https://doi.org/10.14412/2074-2711-2021-6-73-84Test.; Табеева ГР, Осипова ВВ, Филатова ЕГ, Азимова ЮЭ, Амелин АВ, Артеменко АР И др. Диагностика и лечение лекарственно-индуцированной головной боли: рекомендации российских экспертов. Неврология, нейропсихиатрия, психосоматика. 2022;14(1):4–13. https://doi.org/10.14412/2074-2711-2022-1-4-13Test.; https://www.med-sovet.pro/jour/article/view/7928Test

الإتاحة: https://doi.org/10.21518/ms2023-425Test
https://doi.org/10.1016/s1474-4422Test(18)30322-3
https://doi.org/10.1056/NEJMra1915327Test
https://doi.org/10.1016/S0140-6736Test(17)32154-2
https://doi.org/10.1046/j.1526-4610.2001.041007646.xTest
https://doi.org/10.1001/jama.2021.7939Test
https://doi.org/10.1212/wnl.55.6.754Test
https://doi.org/10.1177/0333102411417901Test
https://doi.org/10.1016/S0140-6736Test(20)32342-4
https://doi.org/10.1038/s41582-021-00509-5Test